Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway.
Whole body exposure of wild type control littermates and A2A adenosine receptor (A2AR) gene deleted mice to low oxygen containing inspired gas mixture allowed the investigation of the mechanism that controls inflammatory liver damage and protects the liver using a mouse model of T cell-mediated viral and autoimmune hepatitis. We tested the hypothesis that the inflammatory tissue damage-associated hypoxia and extracellular adenosine --> A2AR signaling plays an important role in the physiological anti-inflammatory mechanism that limits liver damage during fulminant hepatitis. After induction of T cell-mediated hepatitis, mice were kept in modular chambers either under normoxic (21% oxygen) or hypoxic (10% oxygen) conditions for 8 h. It was shown that the whole body exposure to hypoxic atmosphere caused tissue hypoxia in healthy animals as evidenced by a decrease in the arterial blood oxygen tension and increase of the plasma adenosine concentration (P < 0.05). This "hypoxic" treatment resulted in significantly reduced hepatocellular damage and attenuated levels of serum cytokines in mice with acute liver inflammation. The anti-inflammatory effects of hypoxia were not observed in the absence of A2AR in studies of A2AR gene-deficient mice or when A2AR have been pharmacologically antagonized with synthetic antagonist. The presented data demonstrate that total body hypoxia-triggered pathway provides protection in acute hepatitis and that hypoxia (upstream) and A2AR (downstream) function in the same immunosuppressive and liver tissue-protecting pathway.
Choukèr
Alexander
A
Department of Anesthesiology Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.
Thiel
Manfred
M
Lukashev
Dmitriy
D
Ward
Jerrold M
JM
Kaufmann
Ines
I
Apasov
Sergey
S
Sitkovsky
Michail V
MV
Ohta
Akio
A
D000241:Adenosine / Q000378:metabolism; D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D003208:Concanavalin A / Q000378:metabolism; D016207:Cytokines / Q000097:blood; D006505:Hepatitis / Q000378:metabolism / Q000473:pathology / Q000821:virology; D006801:Humans; D000860:Hypoxia; D007249:Inflammation / Q000378:metabolism*; D008099:Liver / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010100:Oxygen / Q000097:blood; D011687:Purines / Q000097:blood; D043705:Receptor, Adenosine A2A / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology*; D013601:T-Lymphocytes / Q000276:immunology; D014227:Triazines / Q000378:metabolism; D014230:Triazoles / Q000378:metabolism
D058917:Adenosine A2 Receptor Antagonists; D016207:Cytokines; D011687:Purines; D043705:Receptor, Adenosine A2A; D014227:Triazines; D014230:Triazoles; C097270:ZM 241385; D003208:Concanavalin A; D000241:Adenosine; D010100:Oxygen